14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
AKTX vs EQ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 53.0/100 (HOLD) at $6.71 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. +0.0% YoY).
Technical & Structure Timing Caution: AKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTX vs EQ. Trailing 12-month operating profitability (AKTX 0.0% vs EQ 0.0%) and valuation multiples (AKTX N/M vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKTX vs EQ Key Questions & Quantitative Answers
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Akari Therapeutics plc (AKTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 53.0/100 (HOLD) at $6.71 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKTX currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. +0.0% YoY). Technical & Structure Timing Caution: AKTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EQ leads the Growth & Scale pillar: AKTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, AKTX generates N/A in USD-normalized revenue versus $4.4M for EQ. In operating R&D and SG&A reinvestment, AKTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.
EQ screens cheaper on headline valuation multiples. AKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTX (-146.3% ROE) versus EQ (-59.0% ROE) capital efficiency.
In options market volatility and institutional positioning, AKTX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (81.68β · 145% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.